December 2016

New Product - Empliciti

Empliciti (elotuzumab) is an immunostimulatory humanised IgG1 recombinant monoclonal antibody that specifically targets the SLAMF7 (signaling lymphocyte activation molecule family member 7) protein. SLAMF7 is highly expressed on multiple myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on natural killer cells, natural killer T cells, plasma cells, and at lower levels on some CD8+ T cells and other specific immune cell subsets, but is not detected on normal solid tissues or hemopoietic stem cells. Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Empliciti is used in combination with other medicinal products; therefore, the contraindications applicable to those medicinal products also apply to Empliciti combination therapy. The product information for all medicinal products used in combination with Empliciti must be consulted before starting therapy. Empliciti is available as a powder for infusion, in a single use 20 mL vial containing either 300 mg or 400 mg of elotuzumab in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629